The overexpression of FGFR4 in pancreatic cancer is found to be mediated by an intronic enhancer that is activated by HNF1A, and mutations in the HNF1A-binding site reduced the enhancer activity56. This evidence concerns the gene HNF1A and pancreatic neoplasm.